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Background: Careful assessment of the reasons for discontinuation of active surveillance
(AS) is required for men with prostate cancer (PCa).
Objective: Using Movember's Global Action Plan Prostate Cancer Active Surveillance
initiative (GAP3) database, we report on reasons for AS discontinuation.
Design, setting, and participants: We compared data from 10 296 men on AS from
21 centres across 12 countries.
Outcome measurements and statistical analysis: Cumulative incidence methods were
used to estimate the cumulative incidence rates of AS discontinuation.
Results and limitations: During 5-yr follow-up, 27.5% (95% conﬁdence interval [CI]: 26.4–
28.6%)men showed signs of disease progression,12.8% (95%CI: 12.0–13.6%) converted to active
treatment without evidence of progression, 1.7% (95% CI: 1.5–2.0%) continued to watchful
waiting, and 1.7% (95% CI: 1.4–2.1%) died fromother causes. Of the 7049menwho remained on
AS, 2339had follow-up for>5 yr, 4561had follow-up for<5 yr, and149were lost to follow-up.
Cumulative incidence of progressionwas 27.5% (95% CI: 26.4–28.6%) at 5 yr and 38.2% (95% CI:
36.7–39.9%) at 10 yr. A limitation is that not all centres were included due to limited
information on the reason for discontinuation and limited follow-up.
Conclusions: Our descriptive analyses of current AS practices worldwide showed that
43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease
progression. Improvements in selection tools for AS are thus needed to correctly allocate
men with PCa to AS, which will also reduce discontinuation due to conversion to active
treatment without evidence of disease progression.
Patient summary: Our assessment of a worldwide database of men with prostate cancer
(PCa) on active surveillance (AS) shows that 43.6% drop out of ASwithin 5 yr, mainly due to
signs of disease progression. Better tools are needed to select andmonitormenwith PCa as
part of AS.
ssoc© 2018 European Ay The Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) con-
sortium members are presented in the Supplementary material[3_TD$DIFF].
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About 2 decades ago, the concept of active surveillance (AS)
was introduced as a management strategy for menwith low-
risk prostate cancer (PCa) [1]. Men are monitored closely
through repeated prostate-specific antigen (PSA) measure-
ments, biopsies, and potentially also magnetic resonance
imaging (MRI), with the intention to start curative treatment
when their PCa is reclassified as higher risk due to signs of
progression (ie, clinical or pathological) and to minimise the
harm caused by the overtreatment of indolent cancer
[2]. However, even though AS has no long-term physical
morbidity, studies continue to report that 1.6–38% of men opt
outofAS,oftenwithnoorlittleevidenceofdiseaseprogression,
within 5 yr [3]. Thus, men embarking on AS are likely to
transition to an alternative strategy within a decade, which
highlights the need for more insight into AS protocols [1,4].
Careful assessment of reasons for discontinuation of AS is
required, especially since treatment pathways for menwith
low-risk PCa vary by country and aremanaged differently in
various healthcare systems [5,6]. It is unclear whether a
decrease in health-related quality of life in men on AS
precipitates their transition to radical treatment or whether
this is driven by the distress over disease progression,
physiological symptoms, or the burden of age. Most studies
are small and with short follow-up [7–10]. Better under-
standing of reasons for opting out of AS is thus needed to
help define a management strategy for AS.
Hence, in 2014, the Movember Foundation launched the
Global Action Plan Prostate Cancer Active Surveillance
initiative (GAP3), which covers the largest centralised PCa
AS database to date (https://gap3.movemberprojects.com).
Its primary goal is to create a global consensuswith uniform
guidelines on the selection and monitoring of men with
low-risk PCa [11]. Here, we report on adherence to AS and
the reasons for discontinuation by comparing data from
10296 men on AS from 21 different centres across
12 different countries.
2. Patients and methods
2.1. Study population
Between 2014 and 2016, the global GAP3 database was created by
combining patient data from established AS cohorts worldwide.
Requirements for participation included, amongst others, ethical
approval for sharing digital patient data in a centralised global database
and active registry of AS patients over the last 2 yr or more, including at
least 50 patients annually. To date, 25 centres from the USA, Canada,
Australasia, the UK, and Europe fulﬁlled the requirements for participa-
tion and joined the initiative [11], resulting in data for a total of
15 101men on AS. For the current study, we excluded 3084 patients from
Dublin,MDAnderson Cancer Centre, Toronto, and University ofMichigan
and Michigan Urological Surgery Improvement Collaborative, as these
centres did not distinguish between progression and anxiety events.
Furthermore, to ensure as much homogeneity in our AS cohort as
possible, we included only menwith a Gleason grade group of 1, leaving
10 296 patients for the ﬁnal analysis. Each institution obtained
institution ethical approval and signed a Movember end user license
agreement, an access rights principles agreement, and the commonly
agreed upon GAP3 analytical plan.Although there are many variations in existing protocols, most
agreed that the most suitable patients for AS are those with age >18 yr,
pretreatment clinical stage T1–T2, serum PSA 10 ng/ml, a biopsy
Gleason grade group of 1 or 2, and a maximum of two tumour-positive
biopsy core samples. The AS inclusion criteria for the 25 centres are
shown in Supplementary Table 1 [11]. Some protocols included PSA
density (most often using a cut-off of 0.2 ng/ml), the maximum extent of
cancer per core (most often using a cut-off of 50%), life expectancy of
>10 yr, and adequate biopsy sampling as inclusion criteria for AS. An
overview of contemporary worldwide AS practices across theworld (and
included in GAP3) can also be found in the systematic review by Kinsella
et al. [3] and the cohort proﬁle of the GAP3 database [5].
Following initiation of AS, almost all protocols recommended serial
measurements (with a variation in time intervals) of serum PSA levels,
digital rectal examination, and surveillance biopsy sampling in order to
identify pathological progression. Several protocols considered MRI for
routine use in AS, again with many differences between recommended
frequencies. An overview of the AS follow-up protocols of the
25 institutes included in GAP3 is given in Supplementary Table 2 [11].
In addition to baseline criteria for selection and monitoring of AS, the
GAP3 database also contains information on discontinuation of AS (ie, the
reasons for stopping AS), and potential following treatments (eg, radical
prostatectomy) and cause of death. Each centre reports for each patient an
event time, deﬁned as the time from the patient's AS initiation to
discontinuation of AS due to “conversion to watchful waiting”, “clinical
progression”, “pathological progression”, “clinical and pathological pro-
gression”, “PSA progression (PSA doubling time <3 yr)”, “other PSA
kinetics”, “patient choice/anxiety”, “doctor's anxiety”, “radiological pro-
gression”, “death”, “loss to follow-up”, “other/unknown reasons”, or “still
beingonAS”. Theseevents aredeﬁnedaccording to the centres’owncriteria.
We used the following coding for deﬁning the signs of disease progression:
“clinical and pathological progression”, “clinical progression”, “other PSA
kinetics”, “pathological progression”, “PSA progression”, and “radiological
progression”. If the reason for discontinuation was classiﬁed as “other/
unknown”, but the “pathological progression status” reported at the time of
AS discontinuation was “Gleason grade group 3 or higher” or the “clinical
progression status” was “cT3 or higher” or “PSA progression status” was
“PSA >20”, the reason for discontinuation was also classiﬁed as signs of
disease progression. The term “sign of disease progression” as used in this
manuscript can thus refer to risk reclassiﬁcation or disease progression as
such. Conversion to active treatment without evidence of disease
progression includes those patients for whom there was no information
on speciﬁc discontinuation or disease progression (according to the criteria
described above) and for whom speciﬁc treatment information was
available, as well as those for whom the reason for discontinuation was
registered as “doctor's anxiety” or “patient's choice/anxiety”. The distribu-
tion of different types of active treatment has been described in detail in our
recently published cohort proﬁle [11].
2.2. Statistical methods
Descriptive statistics were used to summarise patient characteristics.
The cumulative incidence method was used to estimate the rates of each
event for discontinuation of AS. Cox proportional hazards regression
analyses were used to estimate hazard ratios for various reasons of
discontinuation based on age, PSA, and the number of positive biopsy
cores. To account for the heterogeneity between centres, these models
used the centre as a stratum. R version 3.3.2 (The R Foundation for
Statistical Computing, Vienna, Austria) was used to perform all analyses.
3. Results
Table 1 shows the distribution of men on AS included in this
study according to patient and tumour characteristics, by
Table 1 – Distribution of men on AS according to patient and tumour characteristics, by outcome following AS at 5 yr of follow-up

















Years on AS 3.3 (1.4–5.8) 1.4 ([5_TD$DIFF]1.1–2.5) 1.6 ([6_TD$DIFF]1.0–2.7) 1.7 ([7_TD$DIFF]1.2–3.1) 2.3 ( [8_TD$DIFF]1.5–3.4) <0.01
Year of diagnosis 2010 ([9_TD$DIFF]2007–2013) 2010 ([9_TD$DIFF]2007–2011) 2008 ([10_TD$DIFF]2004–2010) 2010 ([11_TD$DIFF]2009–2010) 2007 ( [12_TD$DIFF] 003–2010) <0.01
Age at start of AS (yr) 65 ([13_TD$DIFF]60–69) 65 ([14_TD$DIFF]61–69) 65 ([13_TD$DIFF]60–69) 72 ([15_TD$DIFF]65–75) 69 ( [15_TD$DIFF]65–73) <0.01
PSA at start of AS (ng/ml) 5.3 ([16_TD$DIFF]3.9–7.2) 5.4 ([17_TD$DIFF]4.2–7.0) 5.6 ([17_TD$DIFF]4.2–7.3) 5.9 ([18_TD$DIFF]4.5–7.5) 6.4 ( [17_TD$DIFF]4.2–9.1) 0.01
Number of biopsy cores with PCa 1 ([19_TD$DIFF] –2) 1 ([19_TD$DIFF] –2) 1 ([19_TD$DIFF] –2) 1 ([19_TD$DIFF] –2) 1 ( [19_TD$DIFF] –2) <0.01
AS = active surveillance; PCa = prostate cancer; PSA = prostate-speciﬁc antigen.
The median and interquartile ranges are provided for each variable.
a Kruskal-Wallis rank sum test.
E U RO P E AN URO L OGY 7 5 ( 2 019 ) 5 2 3 – 5 31 525outcome at 5 yr of follow-up. During 5-yr follow-up, 27.5%
(95% confidence interval [CI]: 26.4–28.6%)men showed signs
of disease progression, 12.8% (95% CI: 12.0–13.6%) converted
to active treatment without evidence of progression, 1.7%
(95% CI: 1.5–2.0%) continued to watchful waiting, and 1.7%
(95% CI:1.4–2.1%) died from other causes. Of the 7049 men
who remained on AS during follow-up, 2339 had follow-up
of >5 yr, 4561 had <5 yr of follow-up, and 149 were lost to
follow-up. Hence, at 5 yr of follow-up, the cumulative
incidence rate of men remaining on AS was 56.4% (95% CI:
55.2–57.6%), and 43.6% (95% CI: 42.4–44.8%) were lost to
follow-up or discontinued AS. Furthermore, the distribution
of outcomes and tumour characteristics per participating









[20_TD$DIFF]EU-Atlanta 5 41 0
[21_TD$DIFF]KB-Baden 44 52 0 2
[22_TD$DIFF]UOF-Calgary 82 346 0 8
[23_TD$DIFF]CUHT-Cambridge 21 162 14 1
[24_TD$DIFF]EMC-Rotterdam 49 18 3 3
[25_TD$DIFF]other PRIAS centres 149 1368 26 39
[26_TD$DIFF]SU-Gothenburg 293 147 1 11
[27_TD$DIFF]HUCH-Helsinki 58 97 1 9
[28_TD$DIFF]JHU-Baltimore 461 315 91 40
[29_TD$DIFF]KU-Kagawa 29 2 1 4
[30_TD$DIFF]CHU-Lille 4 94 10 3
[31_TD$DIFF]GSTT-[32_TD$DIFF]London 58 43 0 8
[1_TD$DIFF]UCL [33_TD$DIFF]-London 30 230 0
[34_TD$DIFF]SUS-Malmö 10 90 1 1
[35_TD$DIFF]MEASCAP-Melbourne 53 114 0 6
[36_TD$DIFF] NT-Milan 102 287 0 24
MSKCC[37_TD$DIFF]-New York 443 344 0 5
[38_TD$DIFF]YUHS-Seoul 0 33 0
[39_TD$DIFF]SGH-Singapore 21 93 0 2
UCSF[40_TD$DIFF]-San Francisco 405 487 0 26
[41_TD$DIFF] VO-Valencia 22 149 0 6
[42_TD$DIFF]UBC-Vancouver 0 49 1 1
Total 2339 4561 149 206
GAP3 = Movember's Global Action Plan Prostate Cancer Active Surveillance initi
MSKCC = Memorial Sloan Kettering Cancer Center; PRIAS = Prostate Cancer Res
UCSF = University of California, San Francisco[43_TD$DIFF]. See appendix A for institute abbreThe cumulative incidence of signs of disease progression
was 27.5% (95% CI: 26.4–28.6%) at 5 yr and 38.2% (95% CI:
36.7–39.9%) at 10 yr. Figure 1 shows the cumulative
incidence for discontinuation based on different events:
signs of progression, conversion to active treatmentwithout
evidence of progression, watchful waiting, death, and still
being on AS. An increase in discontinuation can be observed
after 1 yr, with the largest proportion being due to signs of
disease progression and conversion to active treatment
without evidence of progression. Moreover, it is worth
noting that the proportion of men dying from other causes
increased gradually throughout the follow-up, which
reflects the real-world setting of this database. Finally, it








2 0 0 0 48
2 24 2 1 145
0 30 0 0 538
8 7 1 1 224
3 4 5 0 112
2 136 51 13 2135
1 142 0 43 737
7 9 17 3 282
0 141 0 9 1417
5 19 3 5 104
6 10 0 1 155
3 8 0 2 194
0 10 2 0 272
9 4 1 1 126
3 3 3 0 236
5 51 23 2 710
6 190 0 16 1049
2 1 0 0 36
0 46 0 1 181
2 94 0 11 1259
1 21 10 5 268
4 2 0 2 68
1 952 118 116 10 296
ative; KCL = King's College London; Erasmus MC = Erasmus Medical Center;
earch International Active Surveillance; UCL = University College London;
viations.
[(Fig._1)TD$FIG]
Fig. 1 – Cumulative incidence of discontinuation of active surveillance over time. AS = active surveillance; PCa = prostate cancer.
E U RO P E AN U RO LOGY 7 5 ( 2 019 ) 5 2 3 – 5 31526treatment without evidence of progression remained stable
from about 7 yr onwards; a similar trend was observed for
conversion to watchful waiting. To further understand how
patient characteristics may affect discontinuation of AS, we
generated a forest plot specifically focussing on the effects
of age (in decade), PSA, and more than one positive biopsy
core (Fig. 2). As expected, the strongest positive association
is seen for age with transferring to watchful waiting and
[(Fig._2)TD$FIG]
Fig. 2 – Forest plot showing the association between age, PSA, positive biopsy
CI = confidence interval; HR = hazard ratio; PCa = prostate cancer; PSA = prostatnon-PCa death. Furthermore, more than one positive biopsy
core positively associates with progression and non-PCa
death.
Figure 3 shows the cumulative incidence for discontinu-
ation for each centre included in the GAP3 database. For all
centres, an increase in signs of disease progressionwas also
observed after 1 yr, but the slope of this increase varied
substantially by centre.cores, and different reasons for discontinuation of active surveillance.
e-specific antigen.
[(Fig._3)TD$FIG]
Fig. 3 – Cumulative incidence of discontinuation of active surveillance over time for each centre in the GAP3 database. KCL = King's College London;
MC = Erasmus Medical Center; MSKCC = Memorial Sloan Kettering Cancer Center; PCa = prostate cancer; PRIAS = Prostate Cancer Research International
Active Surveillance; UCL = University College London; UCSF = University of California, San Francisco.
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Basedon thedata fromthe largestASdatabase in theworld,we
observed that after about5 yrof follow-up, about 56.4%ofmenwere still on AS. Substantial variation by centre was observed,
but themain reasons for discontinuationwere signs of disease
progression (27.5% ofmen) and conversion to active treatment
without evidence of disease progression (12.8% of men).
E U RO P E AN U RO LOGY 7 5 ( 2 019 ) 5 2 3 – 5 31528As shown in a recent systematic review by Kinsella et al.
[12], many factors influence men's adherence to AS on
multiple levels. Their thematic assessment of barriers and
facilitators for adherence to AS identifiedmany key themes:
(1) patient and tumour factors (age, comorbidities, knowl-
edge, education, socioeconomic status, family history,
grade, tumour volume, fear of progression/side-effects),
(2) family and social support, (3) provider (speciality,
communication, attitudes), (4) healthcare organisation
(geography, type of practice), and (5) health policy (guide-
lines, year, awareness) [12]. Interestingly, this systematic
review observed that even though a number of studies have
shown that emotional distress is relatively high in men at
the time of their PC diagnosis [13,14], anxiety in men on
long-termAS has been generally reported as favourably low.
More studies have suggested that anxiety in men on AS
reduces [15–17] or remains the same over time [8,17–22].
Our findings of a drop-out rate of 43.6% after about 5 yr
are in line with previous estimations [23]. However, the
proportion of men opting out without evidence for
progression was only 12.8%. The variation observed
between different institutions shows rather distinct pat-
terns with respect to the proportion of men dropping out
due to progression and the proportion of men dropping out
due to conversion to active treatment without evidence of
disease progression. However, part of the reason why the
proportion of drop-out due to conversion to active
treatment without evidence of disease progression was
largest in Memorial Sloan Kettering Cancer Center,
Singapore, Baden, and Goteborg may be explained by the
fact that their median follow-up was about 3–4 yr as
compared with 1–2 yr in most other centres. Nevertheless,
the data fromother centreswith lengthier follow-up such as
John Hopkins University, Valencia, and University of
California San Francisco, still showed the largest proportion
of discontinuation due to disease progression. In this
context, it was also interesting to note that the proportion
of men converting to active treatment without evidence of
progression in our database remained stable after about
7 yr. It can be speculated that more anxious men (and
clinicians) were more likely to make the decision about
discontinuing AS during the first years. It might suggest that
more emphasis on education and support is required during
these first years on AS [12]. Surprisingly, the proportion of
watchful waiting also stabilised after 7 yr, which is
unexpected as the population is growing older. Again, this
observation might be due to different practices across
centres.
The rather large proportion of drop-outs due to signs of
disease progression also highlights the need for better
inclusion/exclusion criteria, better markers of stable dis-
ease, and better outcome measures. For instance, a recent
review by Nowinski et al. [24] showed the need for novel
approaches of classification, including molecular features,
to direct therapy for men with low-grade PCa, especially
those on AS. They concluded that by combining genome-
wide association study data with gene expression and
structural rearrangements, risk alleles were identified,
which could provide a new basis for developing aprognostication tool to guide therapy for men with early
PCa [24,25].
Moreover, the use of MRI as a tool to risk stratify men
with low-risk PCa has been emerging over time. A study by
Thurtle et al. [26] evaluated data from 157 men enrolled on
AS using a protocol including multiparametric MRI, and
noted low progression and treatment conversion rates.
Changes in multiparametric MRI findings were found to be
the principal trigger for detecting progression by imaging
alone or pathologically. In addition, the recent findings of
the PROMIS trial, which was based on men with PSA
concentrations up to 15 ng/ml and with no previous biopsy,
have shown us that MRI identified nearly all men with
clinically significant PCa (93%) versus the current practice
standard (transrectal biopsy), which identified only 48%
[27]. The endotype generated by positiveMRIwas positively
associated with grade and volume, and contained cancer in
most cases (Likert 4 = 92%; Likert 3 = 60%). An update of
the current Movember GAP3 database with information on
MRI images will hence provide us more insight into the use
of MRI as a selection and monitoring tool for AS.
In addition to genetics andMRI, several studies have also
investigated the use of serum biomarkers as a tool to
monitormen on AS. However, a recent systematic review by
Loeb and Tosoian [28] concluded that very few markers
have longitudinal results available yet for men on AS,
indicating an important area for future research where the
GAP3 database will be able to contribute. Furthermore,
simple changes in clinical assessment have been proposed
as a strategy to reduce rates of discontinuation of AS.
Bokhorst et al. [29] have, for example, shown that the
number of positive biopsies should no longer be used to
trigger immediate active treatment, but rather to indicate
further investigation to confirm the suspicion of higher-risk
disease.
The GAP3 database is a unique resource covering data
from all over the world. Some limitations exist, resulting in
not all centres being included in these analyses due to the
lack of information on the reason for discontinuation and
limited follow up. However, even after a follow-up of 5 yr,
we could already observe clear patterns with respect to
reasons for discontinuation. The heterogeneity in study
protocols and data collection across centres can be seen as a
limitation; however, we would like to argue that it is this
real-world setting that adds value to our understanding of
AS. As outlined by PIONEER, the big PCa data consortium of
the European Association of Urology, combination and
analysis of the patient records of men diagnosed with PCa
can enable healthcare systems to provide more efficient
outcome-driven patient-centred interventions [30]. By
providing data from a wide variety of centres, GAP3 has
the power to transform the perspective of all relevant
stakeholders. Recently, Movember has also allocated
additional funding to maintain the database and update
the clinical data annually, thereby prolonging follow-up
time. Furthermore, this provides the opportunity to collect
evidence on imaging (MRI), molecular (genomics) markers,
patient-related outcomes, and more. In addition, it is worth
noting that only qualitative data will not be sufficient to
E U RO P E AN URO L OGY 7 5 ( 2 019 ) 5 2 3 – 5 31 529answer the question about adherence to AS—there is a need
to combine our observations with qualitative studies to
truly understand the patterns of discontinuation [12]. Given
the available data on the natural course of low-risk disease,
the question about whether active monitoring leads to
better outcome and benefit whilst avoiding missing the
window of cure in case of reclassification/progression is
crucial.
5. Conclusions
Our descriptive analyses of current AS practices around the
world showed that about 43.6% of men drop out of AS after
5 yr, mainly due to signs of disease progression—about
12.8% of drop-outs were due to conversion to active
treatment without evidence of progression. Improvements
in selection tools for AS (eg, biomarkers or MRI) are thus
needed to correctly allocate men with PCa to AS, which in
turn will also reduce discontinuation due to conversion to
active treatment without evidence of disease progression.
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